In this review, our perspective is that PI3K/AKT/mTOR pathway activation is related to conventional therapy resistance in breast cancer, including endocrine therapy, HER2-targeted therapy, CDK4/6 and PARP inhibitors, chemotherapy and immunotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.